122 related articles for article (PubMed ID: 30517658)
1. Spinal Pleomorphic Xanthoastrocytoma With a QKI-RAF1 Fusion.
Daoud EV; Wachsmann M; Richardson TE; Mella D; Pan E; Schwarzbach A; Oliver D; Hatanpaa KJ
J Neuropathol Exp Neurol; 2019 Jan; 78(1):10-14. PubMed ID: 30517658
[TBL] [Abstract][Full Text] [Related]
2. Pleomorphic xanthoastrocytoma of the spinal cord: case report and literature review.
Das S; Yip S; Hukin J; Cochrane D; Dunham C
Clin Neuropathol; 2014; 33(3):190-6. PubMed ID: 24495348
[TBL] [Abstract][Full Text] [Related]
3. BRAF-Mutated Pleomorphic Xanthoastrocytoma of the Spinal Cord with Eventual Anaplastic Transformation.
Hong CS; Wang JL; Dornbos D; Joehlin-Price A; Elder JB
World Neurosurg; 2017 Feb; 98():871.e9-871.e15. PubMed ID: 27956254
[TBL] [Abstract][Full Text] [Related]
4. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
[TBL] [Abstract][Full Text] [Related]
5. A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma.
Yde CW; Sehested A; Mateu-Regué À; Østrup O; Scheie D; Nysom K; Nielsen FC; Rossing M
Cancer Genet; 2016 Oct; 209(10):440-444. PubMed ID: 27810072
[TBL] [Abstract][Full Text] [Related]
6. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.
Hsiao SJ; Karajannis MA; Diolaiti D; Mansukhani MM; Bender JG; Kung AL; Garvin JH
Cold Spring Harb Mol Case Stud; 2017 Mar; 3(2):a001396. PubMed ID: 28299358
[TBL] [Abstract][Full Text] [Related]
7. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression.
Koelsche C; Sahm F; Wöhrer A; Jeibmann A; Schittenhelm J; Kohlhof P; Preusser M; Romeike B; Dohmen-Scheufler H; Hartmann C; Mittelbronn M; Becker A; von Deimling A; Capper D
Brain Pathol; 2014 Apr; 24(3):221-9. PubMed ID: 24345274
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.
Jones DT; Kocialkowski S; Liu L; Pearson DM; Ichimura K; Collins VP
Oncogene; 2009 May; 28(20):2119-23. PubMed ID: 19363522
[TBL] [Abstract][Full Text] [Related]
9. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S
PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y
Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma.
Zhang H; Ma XJ; Xiang XP; Wang QY; Tang JL; Yu XY; Xu JH
Curr Oncol; 2023 Feb; 30(2):2405-2416. PubMed ID: 36826144
[TBL] [Abstract][Full Text] [Related]
12. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
14. Cerebellar pleomorphic xanthoastrocytoma in the setting of neurofibromatosis type-I: Does it portend a different prognosis? A case report and systematic review.
Mathkour M; Banerjee S; Werner C; Hanna J; Abou-Al-Shaar H; Dindial R; Scullen T; Boehm L; Tubbs RS; Ware ML
Clin Neurol Neurosurg; 2021 Jan; 200():106346. PubMed ID: 33160715
[TBL] [Abstract][Full Text] [Related]
15. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
[TBL] [Abstract][Full Text] [Related]
16. Response to combined BRAF/MEK inhibition in adult BRAF V600E mutant spinal pilocytic astrocytoma.
Balasubramanian A; Gunjur A; Gan HK; Perchyonok Y; Cher LM
J Clin Neurosci; 2020 Sep; 79():269-271. PubMed ID: 33070910
[TBL] [Abstract][Full Text] [Related]
17. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
[TBL] [Abstract][Full Text] [Related]
18. Impact of Grade on Survival in Pleomorphic Xanthoastrocytoma and Low Prevalence of BRAF V600E Mutation.
Gandham EJ; Goyal-Honavar A; Beno D; Pai R; Balakrishan R; Jasper A; Gowri M; Moorthy RK; Chacko AG; Chacko G
World Neurosurg; 2022 Aug; 164():e922-e928. PubMed ID: 35618235
[TBL] [Abstract][Full Text] [Related]
19. Molecular features of pleomorphic xanthoastrocytoma.
Zou H; Duan Y; Wei D; Zhang Y; Dai J; Li J; Li X; Zhou J; Liu Z; Jin Z; Zhang Z; Yu Y; Hu Z
Hum Pathol; 2019 Apr; 86():38-48. PubMed ID: 30496796
[TBL] [Abstract][Full Text] [Related]
20. Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?
Vaubel R; Zschernack V; Tran QT; Jenkins S; Caron A; Milosevic D; Smadbeck J; Vasmatzis G; Kandels D; Gnekow A; Kramm C; Jenkins R; Kipp BR; Rodriguez FJ; Orr BA; Pietsch T; Giannini C
Brain Pathol; 2021 Jan; 31(1):20-32. PubMed ID: 32619305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
